Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
4
Neutral
5
Bullish
5
Bearish
33
Neutral
5
Bullish
8
Bearish
29
Neutral
0
Bullish
3
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Eris Lifesciences is an Indian branded formulations company focused on chronic and specialist therapies with expanding sterile injectables and biologics capabilities; it develops, manufactures and commercializes products across cardiology, diabetes, dermatology and other specialty areas and now owns EU‑GMP capable biologics and sterile injectable assets after multiple strategic acquisitions.
The Domestic Branded Formulations (DBF) segment delivered steady growth (Q3 DBF revenue Rs.696 crore, +10% YoY) with strong profitability (Q3 DBF EBITDA margin ~36.5% and 9M margin ~37.1%), and management expects FY26 DBF growth of ~12% and Q4 to reflect the full benefit of recent price increases.
Eris has materially improved insulin market positions since the Biocon acquisition: RHI cartridge share tripled (10% Apr‑24 to 28% Dec‑25) and overall RHI+Glargine share rose from 9% to 16%, underpinning a stated objective of 25% market share and in‑house insulin manufacturing ramp at Bhopal.
International business is transitioning to a CDMO‑led growth engine, reporting Q3 revenue Rs.111 crore (+45% YoY) and providing FY27 international visibility of Rs.550–600 crore revenue with EBITDA Rs.180–200 crore, reflecting confirmed contracts, CDMO investments, and planned export scale from AMD and Biologics sites.
Balance sheet and capital allocation: net debt reduced materially from ~4x to ~2x Net Debt/TTM EBITDA, with a targeted <1.5x by Dec‑26 while maintaining Rs.750–800 crore capex guidance for FY26–FY28 to support injectables, insulin/GLP‑1 and CDMO expansion.
Pharmaceuticals & Biotechnology
Pharmaceuticals
19,400 Cr
Low Risk
31.3
37.2
1.5
5.0
1,887.65
1,237.90
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
4708.70 | 21,456 Cr | 29.70 | 5.11 | 1.60 | 17.19 | 23.02 | 14.68 | ||
843.80 | 20,878 Cr | 31.52 | 4.42 | 0.21 | 11.70 | 13.63 | 8.58 | ||
8167.90 | 20,420 Cr | 108.89 | 23.40 | 0.44 | 21.49 | 25.53 | 9.43 | ||
2616.70 | 19,939 Cr | 31.09 | 5.56 | 0.15 | 17.88 | 22.30 | 16.06 | ||
1402.85 | 19,400 Cr | 31.32 | 4.97 | 0.51 | 15.87 | 13.27 | 8.79 | ||
1690.10 | 19,371 Cr | -398.49 | 3.32 | 0.00 | -1.10 | 0.55 | -0.59 | ||
925.25 | 16,606 Cr | 11.71 | 1.80 | 0.54 | 15.38 | 15.37 | 12.39 | ||
| Median: 7 Co. | — | 1690.10 | 19,939 Cr | 31.09 | 4.97 | 0.44 | 15.87 | 15.37 | 9.43 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
ERIS Lifesciences Ltd (ERIS) is currently trading at 1,392.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Eris Lifesciences is an Indian branded formulations company focused on chronic and specialist therapies with expanding sterile injectables and biologics capabilities; it develops, manufactures and commercializes products across cardiology, diabetes, dermatology and other specialty areas and now owns EU‑GMP capable biologics and sterile injectable assets after multiple strategic acquisitions. The Domestic Branded Formulations (DBF) segment delivered steady growth (Q3 DBF revenue Rs.696 crore, +10% YoY) with strong profitability (Q3 DBF EBITDA margin ~36.5% and 9M margin ~37.1%), and management expects FY26 DBF growth of ~12% and Q4 to reflect the full benefit of recent price increases. Eris has materially improved insulin market positions since the Biocon acquisition: RHI cartridge share tripled (10% Apr‑24 to 28% Dec‑25) and overall RHI+Glargine share rose from 9% to 16%, underpinning a stated objective of 25% market share and in‑house insulin manufacturing ramp at Bhopal. International business is transitioning to a CDMO‑led growth engine, reporting Q3 revenue Rs.111 crore (+45% YoY) and providing FY27 international visibility of Rs.550–600 crore revenue with EBITDA Rs.180–200 crore, reflecting confirmed contracts, CDMO investments, and planned export scale from AMD and Biologics sites. Balance sheet and capital allocation: net debt reduced materially from ~4x to ~2x Net Debt/TTM EBITDA, with a targeted <1.5x by Dec‑26 while maintaining Rs.750–800 crore capex guidance for FY26–FY28 to support injectables, insulin/GLP‑1 and CDMO expansion.
Over the past 52 weeks, ERIS Lifesciences Ltd has traded between a low of ₹1,237.90 and a high of ₹1,887.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
ERIS Lifesciences Ltd has a market capitalization of approximately 19,400.30. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
ERIS Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 31.32 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 19,400.30 Cr, ERIS Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
ERIS Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of ERIS Lifesciences Ltd is 31.32. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Operating revenue rose 7% YoY to INR 757 crore, EBITDA increased 8% to INR 274 crore, and net profit rose to INR 279 crore, aided by a deferred tax gain.
Consolidated net profit was ₹281.6 crore and revenue from operations rose 7.3% year-on-year to ₹756.5 crore (also cited as ₹756.56 crore).
The stock gained after consolidated net profit jumped 200.09% year-on-year to ₹281.61 crore in Q4 FY26, alongside steady revenue growth and a dividend announcement.
Eris Lifesciences reported FY25 revenue of ₹2,894 crore and PAT of ₹375 crore.
Earnings Call/Transcript
ERIS Lifesciences Ltd will hold an analysts/investors conference call on 2026-07-29 at 16:30 IST to discuss standalone and consolidated unaudited results for quarter ended June 30, 2026.
Earnings Call/Transcript
Eris Lifesciences will hold an analysts and investors conference call on 2026-07-29 at 16:30 IST to discuss standalone and consolidated unaudited Q1 FY2027 results; Zoom registration link provided.
Board Meeting
ERIS Lifesciences Ltd informed exchanges that its Board will meet on 2026-07-29 to consider and approve standalone and consolidated unaudited financial results for the quarter ended June 30, 2026; trading window remains closed.
Board Meeting
Eris Lifesciences Ltd scheduled Board meeting on 2026-07-29 to consider and approve standalone and consolidated unaudited financial results for quarter ended 2026-06-30; trading window closed until 48 hours after results.
